183 related articles for article (PubMed ID: 15301112)
21. Ocular pharmacokinetics of subconjunctivally administered cyclosporine in the rabbit.
Kalsi GS; Gudauskas G; Bussanich N; Freeman DJ; Rootman J
Can J Ophthalmol; 1991 Jun; 26(4):200-5. PubMed ID: 1889021
[TBL] [Abstract][Full Text] [Related]
22. Comparison of voriconazole concentration in the aqueous humor and vitreous between non-scraped and scraped corneal epithelium groups after topical 1% voriconazole application.
Wei LC; Tsai TC; Tsai HY; Wang CY; Shen YC
Curr Eye Res; 2010 Jul; 35(7):573-9. PubMed ID: 20597643
[TBL] [Abstract][Full Text] [Related]
23. Effect of ocular compression on intraocular penetration of systemic ofloxacin.
Ugurbas SH; Can M; Koksal M; Dincel A; Bozkurt A; Bayar B
Adv Ther; 2007; 24(2):394-401. PubMed ID: 17565931
[TBL] [Abstract][Full Text] [Related]
24. Intraocular tissue plasminogen activator concentrations after subconjunctival delivery.
Lim JI; Maguire AM; John G; Mohler MA; Fiscella RG
Ophthalmology; 1993 Mar; 100(3):373-6. PubMed ID: 8460008
[TBL] [Abstract][Full Text] [Related]
25. Ocular pharmacokinetics profile of different indomethacin topical formulations.
Bucolo C; Melilli B; Piazza C; Zurria M; Drago F
J Ocul Pharmacol Ther; 2011 Dec; 27(6):571-6. PubMed ID: 22059858
[TBL] [Abstract][Full Text] [Related]
26. Vitreous and aqueous penetration of orally and topically administered moxifloxacin.
Fukuda M; Shibata N; Osada H; Yamashiro Y; Sasaki H
Ophthalmic Res; 2011; 46(3):113-7. PubMed ID: 21325873
[TBL] [Abstract][Full Text] [Related]
27. Comparative intraocular penetration of 4 fluoroquinolones after topical instillation.
Chung JL; Lim EH; Song SW; Kim BY; Lee JH; Mah FS; Seo KY
Cornea; 2013 Jul; 32(7):1046-51. PubMed ID: 23615274
[TBL] [Abstract][Full Text] [Related]
28. Management and outcome of retinoblastoma with vitreous seeds.
Manjandavida FP; Honavar SG; Reddy VA; Khanna R
Ophthalmology; 2014 Feb; 121(2):517-24. PubMed ID: 24572675
[TBL] [Abstract][Full Text] [Related]
29. Ocular pharmacokinetics of subconjunctivally versus intravenously administered 6-mercaptopurine.
Gudauskas G; Kumi C; Dedhar C; Bussanich N; Rootman J
Can J Ophthalmol; 1985 Apr; 20(3):110-3. PubMed ID: 4039967
[TBL] [Abstract][Full Text] [Related]
30. Fleroxacin pharmacokinetics in aqueous and vitreous humors determined by using complete concentration-time data from individual rabbits.
Miller MH; Madu A; Samathanam G; Rush D; Madu CN; Mathisson K; Mayers M
Antimicrob Agents Chemother; 1992 Jan; 36(1):32-8. PubMed ID: 1590696
[TBL] [Abstract][Full Text] [Related]
31. Aqueous and vitreous penetration of ciprofloxacin following different modes of systemic administration.
Madu AA; Mayers M; Perkins R; Liu W; Drusano GL; Aswani R; Madu CN; Miller MH
Exp Eye Res; 1996 Aug; 63(2):129-36. PubMed ID: 8983970
[TBL] [Abstract][Full Text] [Related]
32. Retinal safety of oral and topical ofloxacin in rabbits.
Cohen RG; Raizman M; Callina C; Lahav M
J Ocul Pharmacol Ther; 1997 Aug; 13(4):369-79. PubMed ID: 9261772
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics and posterior segment biodistribution of ESBA105, an anti-TNF-alpha single-chain antibody, upon topical administration to the rabbit eye.
Furrer E; Berdugo M; Stella C; Behar-Cohen F; Gurny R; Feige U; Lichtlen P; Urech DM
Invest Ophthalmol Vis Sci; 2009 Feb; 50(2):771-8. PubMed ID: 18757508
[TBL] [Abstract][Full Text] [Related]
34. Ocular topotecan pharmacokinetics following topical administration to rabbits for diffused anterior retinoblastoma.
Taich P; Del Sole M; Buontempo F; Williams G; Winter U; Sgroi M; Chantada G; Schaiquevich P
J Pharm Pharmacol; 2017 May; 69(5):574-581. PubMed ID: 27578324
[TBL] [Abstract][Full Text] [Related]
35. Distribution of verapamil and norverapamil in the eye and systemic circulation after topical administration of verapamil in rabbits.
Siegner SW; Giovanoni RL; Erickson KA; Netland PA
J Ocul Pharmacol Ther; 1998 Apr; 14(2):159-68. PubMed ID: 9572542
[TBL] [Abstract][Full Text] [Related]
36. Ocular pharmacokinetics of dacarbazine following subconjunctival versus intravenous administration in the rabbit.
Kalsi GS; Silver HK; Rootman J
Can J Ophthalmol; 1991 Aug; 26(5):247-51. PubMed ID: 1933662
[TBL] [Abstract][Full Text] [Related]
37. Ability of Mn(2+) to Permeate the Eye and Availability of Manganese-enhanced Magnetic Resonance Imaging for Visual Pathway Imaging via Topical Administration.
Chen Y; Shi CY; Li Y; Hu YT; Han HB; Sun XD; Salvi SS; Ma ZZ
Chin Med J (Engl); 2016 Aug; 129(15):1822-9. PubMed ID: 27453232
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics of the antineoplastic agent 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) in the aqueous and vitreous of rabbit.
Ueno N; Refojo MF; Liu LH
Invest Ophthalmol Vis Sci; 1982 Aug; 23(2):199-208. PubMed ID: 7096015
[TBL] [Abstract][Full Text] [Related]
39. [Pharmacokinetics of puerarin in the aqueous humor and vitreous of rabbit eye following systemic administration].
Deng X; Zhang Q; Hu S; Gao Y; Yan L
Yan Ke Xue Bao; 2006 Dec; 22(4):275-9. PubMed ID: 17378162
[TBL] [Abstract][Full Text] [Related]
40. Human intraocular penetration pharmacokinetics of moxifloxacin 0.5% via topical and collagen shield routes of administration.
Hariprasad SM; Mieler WE; Shah GK; Blinder KJ; Apte RS; Holekamp NM; Thomas MA; Chi J; Prince RA
Trans Am Ophthalmol Soc; 2004; 102():149-55; discussion 155-7. PubMed ID: 15747753
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
